Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A J Duncton

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Organic & Biomolecular Chemistry|March 15, 2017
Enantioselective synthesis of an octahydroindolizine (indolizidine) alcohol using an enzymatic resolutionJing Zhang, Rao Kolluri, Salvador G Alvarez, et al.
Bioorganic & Medicinal Chemistry Letters|December 1, 2009
Oxime derivatives related to AP18: Agonists and antagonists of the TRPA1 receptorJeff Defalco, Daniel Steiger, Amy Gustafson, et al.
The Journal of Organic Chemistry|November 5, 2005
Preparation of substituted pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines via a Pictet-Spengler cyclizationMatthew A J Duncton, Leon M Smith, Sabina Burdzovic-Wizeman, et al.
The Journal of Organic Chemistry|July 21, 2009
Preparation of heteroaryloxetanes and heteroarylazetidines by use of a Minisci reactionMatthew A J Duncton, M Angels Estiarte, Russell J Johnson, et al.
Frontiers in Oncology|December 13, 2021
Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH)David M Wilson, Matthew A J Duncton, Caleb Chang, et al.
Biochemical and Biophysical Research Communications|September 10, 2009
Identification and characterization of novel TRPV4 modulatorsFabien Vincent, Alejandra Acevedo, Margaret T Nguyen, et al.
Progress in Biophysics and Molecular Biology|October 29, 2020
Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage ResponseDavid M Wilson, Ashley M Deacon, Matthew A J Duncton, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2005
Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinaseEvgueni L Piatnitski, Matthew A J Duncton, Alexander S Kiselyov, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2Eric M Gordon, Matthew A J Duncton, Brian J Wang, et al.
Bioorganic & Medicinal Chemistry Letters|January 3, 2006
Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and IIMatthew A J Duncton, Evgueni L Piatnitski, Reeti Katoch-Rouse, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Organic & Biomolecular Chemistry|March 15, 2017
Enantioselective synthesis of an octahydroindolizine (indolizidine) alcohol using an enzymatic resolutionJing Zhang, Rao Kolluri, Salvador G Alvarez, et al.
Bioorganic & Medicinal Chemistry Letters|December 1, 2009
Oxime derivatives related to AP18: Agonists and antagonists of the TRPA1 receptorJeff Defalco, Daniel Steiger, Amy Gustafson, et al.
The Journal of Organic Chemistry|November 5, 2005
Preparation of substituted pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines via a Pictet-Spengler cyclizationMatthew A J Duncton, Leon M Smith, Sabina Burdzovic-Wizeman, et al.
The Journal of Organic Chemistry|July 21, 2009
Preparation of heteroaryloxetanes and heteroarylazetidines by use of a Minisci reactionMatthew A J Duncton, M Angels Estiarte, Russell J Johnson, et al.
Frontiers in Oncology|December 13, 2021
Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH)David M Wilson, Matthew A J Duncton, Caleb Chang, et al.
Biochemical and Biophysical Research Communications|September 10, 2009
Identification and characterization of novel TRPV4 modulatorsFabien Vincent, Alejandra Acevedo, Margaret T Nguyen, et al.
Progress in Biophysics and Molecular Biology|October 29, 2020
Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage ResponseDavid M Wilson, Ashley M Deacon, Matthew A J Duncton, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2005
Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinaseEvgueni L Piatnitski, Matthew A J Duncton, Alexander S Kiselyov, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2Eric M Gordon, Matthew A J Duncton, Brian J Wang, et al.
Bioorganic & Medicinal Chemistry Letters|January 3, 2006
Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and IIMatthew A J Duncton, Evgueni L Piatnitski, Reeti Katoch-Rouse, et al.
Pageof 3